Phase 1/2a Study of ANPD001 in Parkinson Disease

Summary

This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.

Timeline

Start

2024-01-23

Primary completion

2027-03-30

Completion

2030-04-30

Drugs

Indications